Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Агрессивные нефолликулярные лимфомы - диффузная В-клеточная крупноклеточная лимфома, В-клеточная лимфома высокой степени злокачественности с перестройкой генов c-MYC и BCL2/BCL6, первичная медиастинальная В-клеточная лимфома, медиастинальная лимфома серой зоны, лимфома Беркитта, плазмобластная лимфома

Список литературы

  1. Swerdlow S.H. et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon, France: International Agency for Research in Cancer (IARC) / ed. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H T.J. 2017. 585 p.
  2. Lichtenstein A.K. et al. Primary mediastinal lymphoma in adults // Am J Med. Am J Med, 1980. Vol. 68, № 4. P. 509–514.
  3. Cazals-Hatem D. et al. Primary mediastinal large B-cell lymphoma. A clinicopathologic study of 141 cases compared with 916 nonmediastinal large B-cell lymphomas, a GELA (“Groupe d’Etude des Lymphomes de l’Adulte”) study // Am J Surg Pathol. Am J Surg Pathol, 1996. Vol. 20, № 7. P. 877–888.
  4. Delecluse H.J. et al. Plasmablastic lymphomas of the oral cavity: A new entity associated with the human immunodeficiency virus infection // Blood. 1997. Vol. 89, № 4.
  5. Müller A.M. et al. Development of hematopoietic stem cell activity in the mouse embryo // Immunity. 1994. Vol. 1, № 4. P. 291–301.
  6. Melchers F. The pre-B-cell receptor: Selector of fitting immunoglobulin heavy chains for the B-cell repertoire // Nature Reviews Immunology. 2005. Vol. 5, № 7. P. 578–584.
  7. Van Zelm M.C. et al. Replication history of B lymphocytes reveals homeostatic proliferation and extensive antigen-induced B cell expansion // Journal of Experimental Medicine. 2007. Vol. 204, № 3. P. 645–655.
  8. Chen J. et al. Immunoglobulin gene rearrangement in B cell deficient mice generated by targeted deletion of the JH locus // Int Immunol. 1993. Vol. 5, № 6. P. 647–656.
  9. Teng G., Papavasiliou F.N. Immunoglobulin Somatic Hypermutation // Annu Rev Genet. Annual Reviews, 2007. Vol. 41, № 1. P. 107–120.
  10. Yuan D. Regulation of IgM and IgD synthesis in B lymphocytes. II. Translational and post-translational events. // J Immunol. 1984. Vol. 132, № 3. P. 1566–1570.
  11. Natkunam Y. The biology of the germinal center. // Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 2007. P. 210–215.
  12. Raghavan S.C., Hsieh C.-L., Lieber M.R. Both V(D)J Coding Ends but Neither Signal End Can Recombine at the bcl-2 Major Breakpoint Region, and the Rejoining Is Ligase IV Dependent // Mol Cell Biol. American Society for Microbiology, 2005. Vol. 25, № 15. P. 6475–6484.
  13. Sarkozy C., Traverse-Glehen A., Coiffier B. Double-hit and double-protein-expression lymphomas: Aggressive and refractory lymphomas // The Lancet Oncology. 2015. Vol. 16, № 15.
  14. Hu S. et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: A report from the International DLBCL Rituximab-CHOP Consortium Program // Blood. 2013. Vol. 121, № 20.
  15. Steidl C., Gascoyne R.D. The molecular pathogenesis of primary mediastinal large B-cell lymphoma // Blood. Blood, 2011. Vol. 118, № 10. P. 2659–2669.
  16. Masternak K. et al. CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex. Cold Spring Harbor Laboratory Press, 2000. Vol. 14, № 9.
  17. Scholl T., Mahanta S.K., Strominger J.L. Specific complex formation between the type II bare lymphocyte syndrome-associated transactivators CIITA and RFX5 // Proc Natl Acad Sci U S A. Proc Natl Acad Sci U S A, 1997. Vol. 94, № 12. P. 6330–6334.
  18. Blank C., Gajewski T.F., Mackensen A. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: Implications for tumor immunotherapy // Cancer Immunology, Immunotherapy. 2005. Vol. 54, № 4. P. 307–314.
  19. Steidl C. et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers // Nature. Nature, 2011. Vol. 471, № 7338. P. 377–383.
  20. Rimsza L.M. et al. Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project // Blood. Blood, 2004. Vol. 103, № 11. P. 4251–4258.
  21. Twa D.D.W. et al. Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma // Blood. American Society of Hematology, 2014. Vol. 123, № 13. P. 2062–2065.
  22. Dunleavy K., Wilson W.H. Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: Do they require a unique therapeutic approach? // Blood. 2015. Vol. 125, № 1.
  23. Sarkozy C. et al. Gene expression profiling of gray zone lymphoma // Blood Adv. 2020. Vol. 4, № 11.
  24. Барях Е.А. Лимфома Беркитта // Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний; под ред. И.В. Поддубной, В.Г. Савченко. 2018. P. 80–87.
  25. Olszewski A.J., Kurt H., Evens A.M. Defining and treating high-grade B-cell lymphoma, NOS // Blood. 2022. Vol. 140, № 9.
  26. Torka P. et al. Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics // Blood Adv. 2020. Vol. 4, № 2.
  27. Zeng D. et al. Challenges and Opportunities for High-grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangement (Double-hit Lymphoma) // American Journal of Clinical Oncology: Cancer Clinical Trials. 2019. Vol. 42, № 3.
  28. Dolcetti R. et al. A lymphomagenic role for HIV beyond immune suppression? // Blood. 2016. Vol. 127, № 11.
  29. Gebauer N. et al. TP53 mutations are frequent events in double-hit B-cell lymphomas with MYC and BCL2 but not MYC and BCL6 translocations // Leuk Lymphoma. 2015. Vol. 56, № 1.
  30. de Haan L.M. et al. Real-world routine diagnostic molecular analysis for TP53 mutational status is recommended over p53 immunohistochemistry in B-cell lymphomas // Virchows Archiv. 2023.
  31. Тумян Г.С. et al. Диффузная В-клеточная крупноклеточная лимфома // Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний; под ред. И.В. Поддубной, В.Г. Савченко. 2018. P. 58–68.32.
  32. Программное лечение заболеваний системы крови: Сборник алгоритмов диагностики и протоколов лечения заболеваний системы крови. Под ред. В.Г. Савченко. 2012. 1056 p.33.
  33. Савченко В.Г., Паровичникова Е.Н. Острые лейкозы // Клиническая онкогематология: руководство для врачей. Под ред. Волковой М.А.. 2-е изд., перераб. и доп. 2007. P. 409–502.
  34. Burkitt D.P. The discovery of Burkitt’s lymphoma. // Cancer. 1983. Vol. 51, № 10. P. 1777–1786.
  35. Alaggio R. et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms // Leukemia. 2022. Vol. 36, № 7. P. 1720–1748.
  36. Bentz M. et al. Gain of chromosome arm 9p is characteristic of primary mediastinal b-cell lymphoma (MBL): Comprehensive molecular cytogenetic analysis and presentation of a novel MBL cell line // Genes Chromosomes Cancer. 2001. Vol. 30, № 4. P. 393–401.
  37. Zelenetz A.D. et al. B-cell lymphomas. NCCN Clinical Practice Guidelines in Oncology. Version 5.2022. 2022.
  38. Grommes C., DeAngelis L.M. Primary CNS lymphoma // Journal of Clinical Oncology. American Society of Clinical Oncology, 2017. Vol. 35, № 21. P. 2410–2418.
  39. Демина Е.А. et al. Общие принципы диагностики лимфом // Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний; под ред. И.В. Поддубной, В.Г. Савченко. 2018. P. 9–27.
  40. Tilly H. et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. // Ann Oncol. 2015. Vol. 26 Suppl 5. P. v116-25.
  41. Kuderer N.M. et al. A Validated Risk Score for Venous Thromboembolism Is Predictive of Cancer Progression and Mortality // Oncologist. Alphamed Press, 2016. Vol. 21, № 7. P. 861–867.
  42. Santi R.M. et al. PO-03 - Khorana score and histotype predict the incidence of early venous thromboembolism (VTE) in Non Hodgkin Lymphoma (NHL). A pooled data analysis of twelve clinical trials of Fondazione Italiana Linfomi (FIL) // Thromb Res. Elsevier BV, 2016. Vol. 140. P. S177.
  43. Zhuang Y. et al. [Autoimmune hemolytic anemia associated with B-cell chronic lymphoproliferative disorders]. // Zhongguo shi yan xue ye xue za zhi / Zhongguo bing li sheng li xue hui = Journal of experimental hematology / Chinese Association of Pathophysiology. 2013. Vol. 21, № 3. P. 633–636.
  44. Sumi M. et al. [Primary diffuse large B-cell lymphoma of the bone marrow complicated with autoimmune hemolytic anemia and erythroid hypoplasia]. // Rinsho Ketsueki. 2007. Vol. 48, № 7. P. 571–575.
  45. Wan S.-G. et al. Incipient Coombs’ test negative autoimmune hemolytic anemia precedes non-Hodgkin’s lymphoma. // Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2012. Vol. 20, № 1. P. 97–99.
  46. Köksal Y. et al. Autoimmune hemolytic anemia as presenting manifestation of primary splenic anaplastic large cell lymphoma. // Turk J Pediatr. 2006. Vol. 48, № 4. P. 354–356.
  47. Perez I.E. et al. Cancer Therapy-Related Cardiac Dysfunction: An Overview for the Clinician. // Clin Med Insights Cardiol. SAGE PublicationsSage UK: London, England, 2019. Vol. 13. P. 1179546819866445.
  48. Srivastava S., Wood P. Secondary antibody deficiency-causes and approach to diagnosis // Clinical Medicine, Journal of the Royal College of Physicians of London. 2016.
  49. Мухортова О.В. Использование ПЭТ/КТ при лимфопролиферативных заболеваниях // Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний; под ред. И.В. Поддубной, В.Г. Савченко. 2018. P. 168–179.
  50. Pelosi E. et al. Bone marrow disease detection with FDG-PET/CT and bone marrow biopsy during the staging of malignant lymphoma: results from a large multicentre study. // The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of... 2011. Vol. 55, № 4. P. 469–475.
  51. Khan A.B. et al. PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement // Blood. 2013. Vol. 122, № 1. P. 61–67.
  52. Zanotti-Fregonara P., Stabin M.G. New Fetal Radiation Doses for 18F-FDG Based on Human Data // Journal of Nuclear Medicine. Society of Nuclear Medicine, 2017. Vol. 58, № 11. P. 1865–1866.
  53. Goldberg-Stein S. et al. Body CT during pregnancy: utilization trends, examination indications, and fetal radiation doses // AJR Am J Roentgenol. AJR Am J Roentgenol, 2011. Vol. 196, № 1. P. 146–151.
  54. Lowe S. Diagnostic imaging in pregnancy: Making informed decisions // Obstet Med. Obstet Med, 2019. Vol. 12, № 3. P. 116–122.
  55. Кузьмин А.А. et al. Первичная лимфома центральной нервной системы // Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний; под ред. И.В. Поддубной, В.Г. Савченко. 2018. P. 87–93.
  56. Rozenblum L. et al. Role of Positron Emission Tomography in Primary Central Nervous System Lymphoma // Cancers (Basel). 2022. Vol. 14, № 17. P. 4071.
  57. Ahn S.-Y. et al. Prognostic Significance of Interim 11C-Methionine PET/CT in Primary Central Nervous System Lymphoma // Clin Nucl Med. 2018. Vol. 43, № 8. P. e259–e264.
  58. Fekri M.S., Zade M.K., Fatehi S. The association of deep vein thrombosis with cancer treatment modality: Chemotherapy or surgery? // Iran Red Crescent Med J. Kowsar Medical Publishing Company, 2014. Vol. 16, № 9.
  59. Мангасарова Я.К. et al. Терапия агрессивных неходжкинских лимфом у беременных // Клиническая онкогематология. 2020. Vol. 13, № 3. P. 316–321.
  60. Криволапов Ю.А., Леенман Е.Е. Морфологическая диагностика лимфом. КОСТА, Санкт-Петербург, 2006.
  61. Wang Xiao-Xue 1, Huang Xinyue 1, Zhang Lijun Whole body FDG-PET/CT for the assessment of bone marrow infiltration in patients with newly diagnosed lymphoma //Med Clin (Barc). 2020 Jan 24;154(2):61-65. doi: 10.1016/j.medcli.2019.07.022.
  62. Бокерия Л.А., Затевахин И.И., Кириенко А.И. Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений (ВТЭО). // Флебология. 2015. Vol. 4, № 2. P. 3–52.
  63. Кириенко А.И., Галстян Г.М., Савченко В.Г. Профилактика венозных тромбоэмболических осложнений при лимфопролиферативных заболеваниях // Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний; под ред. И.В. Поддубной, В.Г. Савченко. 2018. P. 268–278.
  64. Santi R.M. et al. Khorana score and histotype predicts incidence of early venous thromboembolism in Non-Hodgkin lymphomas: A Pooled-Data analysis of 12 clinical trials of fondazione italiana linfomi (FIL) // Thromb Haemost. Schattauer GmbH, 2017. Vol. 117, № 8. P. 1615–1621.
  65. Шмаков Р.Г., Демина Е.А. Лимфомы и беременность // Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний; под ред. И.В. Поддубной, В.Г. Савченко. 2018. P. 143–150.
  66. Coiffier B. et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: A study by the Groupe d’Etudes des Lymphomes de l’Adulte // Blood. American Society of Hematology, 2010. Vol. 116, № 12. P. 2040–2045.
  67. Feugier P. et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the groupe d’etude des lymphomes de l’adulte // Journal of Clinical Oncology. 2005. Vol. 23, № 18. P. 4117–4126.
  68. Pfreundschuh M. et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group // Lancet Oncology. 2006. Vol. 7, № 5. P. 379–391.
  69. Miller T.P. et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin’s lymphoma // New England Journal of Medicine. 1998. Vol. 339, № 1. P. 21–26.
  70. Horning S.J. et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin’s lymphoma: Eastern Cooperative Oncology Group Study 1484 // Journal of Clinical Oncology. 2004. Vol. 22, № 15. P. 3032–3038.
  71. Persky D.O. et al. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group Study 0014 // Journal of Clinical Oncology. 2008. Vol. 26, № 14. P. 2258–2263.
  72. Wästerlid T. et al. Six cycles of R-CHOP-21 are not inferior to eight cycles for treatment of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Population-based Study. // Ann Oncol. 2018. Vol. 29, № 8. P. 1882–1883.
  73. Cunningham D. et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: A phase 3 comparison of dose intensification with 14-day versus 21-day cycles // The Lancet. Lancet Publishing Group, 2013. Vol. 381, № 9880. P. 1817–1826.
  74. Kwon J. et al. Additional survival benefit of involved-lesion radiation therapy after r-chop chemotherapy in limited stage diffuse large b-cell lymphoma // Int J Radiat Oncol Biol Phys. Elsevier Inc., 2015. Vol. 92, № 1. P. 91–98.
  75. Magomedova A. et al. ABCL-070 Multicenter Randomized Controlled (Comparative) Open Prospective Study to Evaluate the Efficacy of the R-DA-EPOCH-21 and R-mNHL-BFM-90 ± Autologous Hematopoietic Stem Cell Transplantation Programs in Untreated Patients With de Novo Diffuse B-Cell Large Cell Lymphoma With Signs of Poor Prognosis - DLBCL-2015 Protocol // Arch Clin Trials. 2022;2(3):P.1-10..
  76. Oki Y. et al. Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma // Br J Haematol. 2013. Vol. 163, № 5.
  77. Sonnevi K. et al. Excellent survival after R‐Hyper‐CVAD in hospitalized patients with high‐risk large B‐cell lymphoma: The Karolinska experience // EJHaem. 2021. Vol. 2, № 4.
  78. Boyle E.M. et al. Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014-04 (Etoile du Nord) trial // Br J Haematol. Blackwell Publishing Ltd, 2019. Vol. 187, № 3. P. 319–327.
  79. Illidge T. et al. Modern radiation therapy for nodal non-hodgkin lymphoma - Target definition and dose guidelines from the international lymphoma radiation oncology group // International Journal of Radiation Oncology Biology Physics. Elsevier Inc., 2014. Vol. 89, № 1. P. 49–58.
  80. Held G. et al. Role of radiotherapy to bulky disease in elderly patients with aggressive b-cell lymphoma // Journal of Clinical Oncology. American Society of Clinical Oncology, 2014. Vol. 32, № 11. P. 1112–1118.
  81. Shi Z. et al. Renewed interest in the role of consolidative radiotherapy in advanced stage diffuse large B-cell lymphoma // Leukemia and Lymphoma. 2013. Vol. 54, № 10. P. 2122–2130.
  82. Dabaja B.S. et al. Radiation for diffuse large B-cell lymphoma in the rituximab era: Analysis of the National Comprehensive Cancer Network lymphoma outcomes project // Cancer. John Wiley and Sons Inc., 2015. Vol. 121, № 7. P. 1032–1039.
  83. Tilly H. et al. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma // N Engl J Med. N Engl J Med, 2022. Vol. 386, № 4. P. 351–363.
  84. Martino R. et al. Cyclophosphamide, pegylated liposomal doxorubicin (Caelyx), vincristine and prednisone (CCOP) in elderly patients with diffuse large B-cell lymphoma: results from a prospective phase II study. // Haematologica. Haematologica, 2002. Vol. 87, № 8. P. 822–827.
  85. Zaja F. et al. CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma // Leuk Lymphoma. Leuk Lymphoma, 2006. Vol. 47, № 10. P. 2174–2180.
  86. Moccia A.A. et al. R-CHOP with Etoposide Substituted for Doxorubicin (R-CEOP): Excellent Outcome in Diffuse Large B Cell Lymphoma for Patients with a Contraindication to Anthracyclines. // Blood. American Society of Hematology, 2009. Vol. 114, № 22. P. 408–408.
  87. Fields P.A. et al. De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: A United Kingdom National Cancer Research Institute trial // Journal of Clinical Oncology. American Society of Clinical Oncology, 2014. Vol. 32, № 4. P. 282–287.
  88. Han S.M. et al. Primary splenic lymphoma associated with hemophagocytic lymphohistiocytosis complicated with splenic rupture // Journal of the Chinese Medical Association. Elsevier (Singapore) Pte Ltd, 2008. Vol. 71, № 4. P. 210–213.
  89. Salles G. et al. Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience // Advances in Therapy. 2017. Vol. 34, № 10. P. 2232–2273.
  90. Raefsky E.L. et al. Brief duration rituximab(R)/chemotherapy (CNOP or CVP) followed by maintenance rituximab in elderly/poor performance status patients (pts) with diffuse large B-cell lymphoma (DLBCL): A phase II trial of the Minnie Pearl Cancer Research Network // Journal of Clinical Oncology. American Society of Clinical Oncology, 2006. Vol. 24, № 18_suppl. P. 7577–7577.
  91. Olmos-Jiménez R. et al. Practical aspects of the use of intrathecal chemotherapy Aspectos prácticos de la utilización de quimioterapia intratecal // Farm Hosp. 2017. Vol. 41, № 1. P. 105–129.
  92. Martín M.C. et al. Methotrexate embryopathy after exposure to low weekly doses in early pregnancy // Reproductive Toxicology. 2014. Vol. 43. P. 26–29.
  93. Бобкова М.М. et al. Эффективность применения интенсивной полихимиотерапии в лечении молодых больных с диффузной В-крупноклеточной лимфомой из клеток герминального центра // Онкогематология. 2009. Vol. 4. P. 4–11.
  94. Sonnevi K. et al. Excellent survival after R-Hyper-CVAD in hospitalized patients with high-risk large B-cell lymphoma: The Karolinska experience // EJHaem. John Wiley & Sons, Ltd, 2021. Vol. 2, № 4. P. 774–784.
  95. McMillan A.K. et al. Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3-5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial // Ann Oncol. Ann Oncol, 2020. Vol. 31, № 9. P. 1251–1259.
  96. Магомедова А.У. et al. Промежуточные результаты многоцентрового, рандомизированного, контролируемого (сравнительного) открытого, проспективного исследования по оценке эффективности программ R-DA-EPOCH-21, R-MNHL-BFM-90 и трансплантации аутологичных стволовых кроветворных клеток // Гематология и трансфузиология. 2020. Vol. 65, № S1. P. 35.
  97. Visco C. et al. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: A report from the International DLBCL Rituximab-CHOP Consortium Program Study // Leukemia. 2012. Vol. 26, № 9.
  98. Паровичникова Е.Н. и другие. «Алгоритмы диагностики и протоколы лечения заболеваний системы крови» / ed. Паровичникова Е.Н. Москва: Практика, 2024. Vol. 2.
  99. Gabeeva N.G. et al. Successful experience of treatment of a patient with generalized non-GCB- DLBCL using the R-mNHL-BFM-90 protocol with lenalidomide: Case report and review of literature // Ter Arkh. CJSC Consilium Medicum, 2018. Vol. 90, № 7. P. 96–101.
  100. Gabeeva N.G. et al. CHEMOTHERAPY ACCORDING TO THE R-mNHL-BFM-90 PROTOCOL IN COMBINATION WITH LENALIDOMIDE AS THE FIRST LINE THERAPY IN PATIENTS WITH MUM1-POSITIVE DIFFUSIVE LARGE B-CELL LYMPHOMA AND FOLLICULAR LYMPHOMA GRADE 3B // Russian journal of hematology and transfusiology. 2019. Vol. 64, № 2. P. 150–164.
  101. Tilly H. et al. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma // New England Journal of Medicine. 2022. Vol. 386, № 4.
  102. Габеева Н.Г. и другие. Результаты терапии больных «double-hit» лимфомой  (DHL) по протоколу R-mNHL-BFM-90 в комбинации с таргетными препаратами. // Гематология и трансфузиология. 2024. Vol. 69. P. 191–192.
  103. Zelenetz A.D. et al. Early Results Indicate Acceptable Safety and Promising Efficacy of Venetoclax in Combination with Pola-R-CHP for Untreated High-Risk BCL-2-Positive B-Cell Lymphoma Including Double/Triple Hit Lymphoma // Blood. 2023. Vol. 142, № Supplement 1.
  104. Goy A. et al. Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non–germinal center B-cell–like DLBCL // Blood. 2019. Vol. 134, № 13.
  105. Perry C. et al. Characteristics, management and outcome of DLBCL patients, presenting with simultaneous systemic and CNS disease at diagnosis: A retrospective multicenter study // Am J Hematol. Wiley-Liss Inc., 2019. Vol. 94, № 9. P. 992–1001.
  106. Westin J. et al. Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma // Journal of Clinical Oncology. 2023. Vol. 41, № 4.
  107. Xu P.P. et al. Ibrutinib, rituximab, and lenalidomide in unfit or frail patients aged 75 years or older with de novo diffuse large B-cell lymphoma: a phase 2, single-arm study // Lancet Healthy Longev. 2022. Vol. 3, № 7.
  108. Bohers E. et al. Molecular Characterisation of Diffuse Large B Cell Lymphoma in Patients of 80 Years Old or More: Clinical Relevance in a Multicentric Randomized Phase III Study of the Lysa (SENIOR Study) // Blood. 2019. Vol. 134, № Supplement_1.
  109. Gavrilina O.A. et al. Addition of R-HMA to R-DA-EPOCH Favourably Changes the Outcome in Patients with Untreated High-Grade Diffuse Large B-Cell Lymphoma: The First Results of Russian Prospective Multicenter Trial // Blood. 2015. Vol. 126, № 23.
  110. Peyrade F. et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: A multicentre, single-arm, phase 2 trial // Lancet Oncol. 2011. Vol. 12, № 5. P. 460–468.
  111. Peyrade F. et al. Long-term follow-up of the GELA LNH 03-7B study: A prospective phase II study of 150 patients over 80 years with diffuse large B-cell lymphoma (DLBCL) treated with RminiCHOP. // Journal of Clinical Oncology. American Society of Clinical Oncology, 2013. Vol. 31, № 15_suppl. P. 8536.
  112. Laribi K. et al. R-CVP regimen is active in frail elderly patients aged 80 or over with diffuse large B cell lymphoma // Ann Hematol. Springer Verlag, 2016. Vol. 95, № 10. P. 1705–1714.
  113. Arakaki H. et al. Comparison of R-CVP with R-CHOP for very elderly patients aged 80 or over with diffuse large B cell lymphoma // Annals of Hematology. Springer Verlag, 2017. Vol. 96, № 7. P. 1225–1226.
  114. Zeremski V. et al. Is bendamustine-rituximab a reasonable treatment in selected older patients with diffuse large B cell lymphoma? Results from a multicentre, retrospective study // Ann Hematol. Springer, 2019. Vol. 98, № 12. P. 2729–2737.
  115. Storti S. et al. Rituximab plus bendamustine as front-line treatment in frail elderly (>70 years) patients with diffuse large b-cell non-hodgkin lymphoma: A phase ii multicenter study of the fondazione italiana linfomi // Haematologica. Ferrata Storti Foundation, 2018. Vol. 103, № 8. P. 1345–1350.
  116. Zinzani P.L. et al. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: A retrospective study // Clin Lymphoma Myeloma. Cancer Information Group, LP, 2009. Vol. 9, № 5. P. 381–385.
  117. Вернюк М.А. et al. Опыт лечения первичной медиастинальной В-крупноклеточной лимфомы // Онкогематология. 2013. Vol. 4. P. 18–23.
  118. Тумян Г.С. Первичная медиастинальная В-крупноклеточная лимфома: диагностика, клиническая картина и лечение // Современная онкология. 2008. Vol. 10, № 3. P. 66–68.
  119. Dunleavy K. et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma // New England Journal of Medicine. Massachussetts Medical Society, 2013. Vol. 368, № 15. P. 1408–1416.
  120. Chan E.H.L. et al. Real world experience of R-CHOP with or without consolidative radiotherapy vs DA-EPOCH-R in the first-line treatment of primary mediastinal B-cell lymphoma // Cancer Med. Blackwell Publishing Ltd, 2019. Vol. 8, № 10. P. 4626–4632.
  121. Мангасарова Я.К. et al. Первичная медиастинальная (тимическая) В-крупноклеточная лимфома: диагностика отдаленных экстрамедиастинальных поражений и возможности лечения // Клиническая онкогематология. 2018. Vol. 11, № 3. P. 220–226.
  122. Derenzini E. et al. Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 01) diffuse large B-cell lymphoma // Leuk Lymphoma. Taylor & Francis, 2009. Vol. 50, № 11. P. 1824–1829.
  123. Мангасарова Я.К. ПЕРВЫЕ РЕЗУЛЬТАТЫ ТЕРАПИИ ПЕРВИЧНОЙ МЕДИАСТИНАЛЬНОЙ В-КРУПНОКЛЕТОЧНОЙ ЛИМФОМЫ ПО ПРОГРАММЕ R-DA-EPOCH - 21 // Терапевтический архив. 2016. Vol. 7.
  124. Zinzani P.L. et al. Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170 // Blood. 2023. Vol. 142, № 2.
  125. Kuruvilla J. et al. Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 study // Leuk Lymphoma. 2023. Vol. 64, № 1.
  126. Renaud L et al. Nivolumab combined with brentuximab vedotin with or without mediastinal radiotherapy for relapsed/refractory primary mediastinal large B-cell lymphoma. // Haematologica. . 2024.
  127. Габеева Н.Г. и другие. ПРОМЕЖУТОЧНЫЕ РЕЗУЛЬТАТЫ ТЕРАПИИ ПЕРВИЧНОЙ МЕДИАСТИНАЛЬНОЙ В-КРУПНОКЛЕТОЧНОЙ ЛИМФОМЫ ПО ПРОТОКОЛАМ «ПМЛ-16» И «ПМЛ-19» // Гематология и трансфузиология. 2022. Vol. 67. P. 328–350.
  128. Zucca E. et al. Observation vs. radiotherapy in primary mediastinal B-cell lymphoma patients with complete response to standard immunochemotherapy: The IELSG37 randomized trial. // Journal of Clinical Oncology. 2023. Vol. 41, № 17_suppl. P. LBA7505–LBA7505.
  129. Thiel E. et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial // Lancet Oncol. 2010. Vol. 11, № 11. P. 1036–1047.
  130. Ferreri A.J. et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial // The Lancet. 2009. Vol. 374, № 9700. P. 1512–1520.
  131. Rubenstein J.L. et al. How I treat CNS lymphomas // Blood. The American Society of Hematology, 2013. Vol. 122, № 14. P. 2318–2330.
  132. Chamberlain M.C., Johnston S.K. High-dose methotrexate and rituximab with deferred radiotherapy for newly diagnosed primary B-cell CNS lymphoma. // Neuro Oncol. 2010. Vol. 12, № 7. P. 736–744.
  133. Holdhoff M. et al. High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma // Neurology. Lippincott Williams and Wilkins, 2014. Vol. 83, № 3. P. 235–239.
  134. Omuro A. et al. Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: An intergroup ANOCEF-GOELAMS randomised phase 2 trial // Lancet Haematol. Elsevier Ltd, 2015. Vol. 2, № 6. P. e251–e259.
  135. Morris P.G. et al. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: Final results and long-term outcome // Journal of Clinical Oncology. American Society of Clinical Oncology, 2013. Vol. 31, № 31. P. 3971–3979.
  136. Fritsch K. et al. Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly. // Ann Oncol. 2011. Vol. 22, № 9. P. 2080–2085.
  137. Звонков Е.Е. и другие. Высокодозная химиотерапия первичной диффузной В-крупноклеточной лимфомы центральной нервной системы. Промежуточные результаты протокола „CNS-2015“. // Гематология и трансфузиология. 2019. Vol. 64(4). P. 447–461.
  138. Omuro A. et al. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma // Blood. 2015. Vol. 125, № 9.
  139. Звонков Е.Е. и другие. Первый опыт терапии больных первичной диффузной В-крупноклеточной лимфомой центральной нервной системы (ПДВККЛ ЦНС) по протоколу «CNS-2021». // Гематология и трансфузиология. 2022. Vol. 67(2). P. 203–204.
  140. Звонков Е.Е. et al. Высокодозная химиотерапия первичной диффузной В-крупноклеточной лимфомы центральной нервной системы. Промежуточные результаты протокола CNS-2015 // Гематология и трансфузиология. 2019. Vol. 64, № 4. P. 447–461.
  141. Omuro A. et al. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. // Blood. Blood, 2015. Vol. 125, № 9. P. 1403–1410.
  142. Alnahhas I. et al. Autologous Stem-Cell Transplantation for Primary Central Nervous System Lymphoma: Systematic Review and Meta-analysis // Clin Lymphoma Myeloma Leuk. 2019. Vol. 19, № 3. P. e129–e141.
  143. Ferreri A.J.M. et al. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: Results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial // Lancet Haematol. Elsevier Ltd, 2016. Vol. 3, № 5. P. e217–e227.
  144. Wirsching H.G. et al. Targeted therapies and immune checkpoint inhibitors in primary cns lymphoma // Cancers. 2021. Vol. 13, № 12.
  145. Wong E.T. et al. Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas // Cancer. 2004. Vol. 101, № 1. P. 139–145.
  146. Yahalom J. et al. Modern radiation therapy for extranodal lymphomas: Field and dose guidelines from the international lymphoma radiation oncology group // Int J Radiat Oncol Biol Phys. Elsevier Inc., 2015. Vol. 92, № 1. P. 11–31.
  147. Fox C.P. et al. Guidelines for the diagnosis and management of primary central nervous system diffuse large B‐cell lymphoma // Br J Haematol. 2019. Vol. 184, № 3. P. 348–363.
  148. Tabouret E. et al. Patterns of response and relapse in primary CNS lymphomas after first-line chemotherapy: imaging analysis of the ANOCEF-GOELAMS prospective randomized trial // Neuro Oncol. 2016. P. now238.
  149. Omuro A. et al. Primary CNS lymphoma in patients younger than 60: can whole-brain radiotherapy be deferred? // J Neurooncol. 2011. Vol. 104, № 1. P. 323–330.
  150. Slade A.N., Stanic S. The impact of RTOG 0614 and RTOG 0933 trials in routine clinical practice: The US Survey of Utilization of Memantine and IMRT planning for hippocampus sparing in patients receiving whole brain radiotherapy for brain metastases // Contemp Clin Trials. 2016. Vol. 47. P. 74–77.
  151. Maschan A. et al. Rituximab and reduced-intensity chemotherapy in children and adolescents with mature B-cell lymphoma: interim results for 231 patients enrolled in the second Russian-Belorussian multicentre study B-NHL-2010M // Br J Haematol. Blackwell Publishing Ltd, 2019. Vol. 186, № 3. P. 477–483.
  152. Kane E. et al. Emergency admission and survival from aggressive non-Hodgkin lymphoma: A report from the UK’s population-based Haematological Malignancy Research Network // Eur J Cancer. Elsevier Ltd, 2017. Vol. 78. P. 53–60.
  153. Senbanjo I.O. Tumor lysis and acute renal failure in Burkitt′s lymphoma: A review on pathophysiology and management // Indian Journal of Nephrology. 2009. Vol. 19, № 3. P. 83–86.
  154. Oosten L.E.M. et al. Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens. // Ann Hematol. 2018. Vol. 97, № 2. P. 255–266.
  155. Dunleavy K. Approach to the Diagnosis and Treatment of Adult Burkitt’s Lymphoma // J Oncol Pract. American Society of Clinical Oncology (ASCO), 2018. Vol. 14, № 11. P. 665–671.
  156. Doocey R.T. et al. Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma. // Br J Haematol. 2005. Vol. 131, № 2. P. 223–230.
  157. S.Carras et al. Dramatic efficacy of low dose lenalidomide as single agent in a patient with refract gastric non-human immunodefi ciency virus-associated plasmablastic lymphoma // Ann Hematol . 2015. Vol. 95. P. 1715–1717.
  158. Yanamandra U. et al. Plasmablastic lymphoma: successful management with CHOP and lenalidomide in resource constraint settings // Annals of Hematology. 2016. Vol. 95, № 10.
  159. Hess B.T. et al. Outcomes of patients with limited-stage plasmablastic lymphoma: A multi-institutional retrospective study // Am J Hematol. 2023. Vol. 98, № 2.
  160. Ryu Y.K. et al. Targeting CD38 with Daratumumab Plus Chemotherapy for Patients with Advanced-Stage Plasmablastoid Large B-Cell Lymphoma // J Clin Med. 2022. Vol. 11, № 16.
  161. Castillo J.J. et al. Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma // British Journal of Haematology. 2019. Vol. 184, № 4.
  162. Попова М.О. et al. Плазмобластная лимфома у пациентов с ВИЧ-инфекцией: обзор литературы и результаты Российского многцентрового ретроспективного исследования. // Клиническая онкогематология. 2022. Vol. 15(1). P. 28–41.
  163. Velasquez W S. et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood (1988) 71 (1): 117–122.
  164. Velasquez W.S. et al. ESHAP - An effective chemotherapy regimen in refractory and relapsing lymphoma: A 4-year follow-up study // Journal of Clinical Oncology. American Society of Clinical Oncology, 1994. Vol. 12, № 6. P. 1169–1176.
  165. Zelenetz A.D. et al. Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin’s lymphoma // Annals of Oncology. 2003. Vol. 14, № SUPPL. 1.
  166. Crump M. et al. Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: A phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) // Cancer. Cancer, 2004. Vol. 101, № 8. P. 1835–1842.
  167. Corazzelli G. et al. Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma. // Cancer Chemother Pharmacol. 2009. Vol. 64, № 5. P. 907–916.
  168. Chau I. et al. An oxaliplatin-based chemotherapy in patients with relapsed or refractory intermediate and high-grade non-Hodgkin’s lymphoma // Br J Haematol. 2001. Vol. 115, № 4. P. 786–792.
  169. Amorim S. et al. Consolidation therapy with mitoxantrone, ifosfamide and etoposide with or without rituximab before stem cell transplantation in relapsed diffuse large B-cell lymphoma patients failing second-line treatment // Leukemia and Lymphoma. Taylor and Francis Ltd, 2016. Vol. 57, № 10. P. 2425–2428.
  170. Herrera A.F. et al. Polatuzumab Vedotin Combined with R-ICE (PolaR-ICE) As Second-Line Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma // Blood. 2022. Vol. 140, № Supplement 1. P. 1065–1067.
  171. Philip T. et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-hodgkin’s lymphoma // New England Journal of Medicine. 1995. Vol. 333, № 23. P. 1540–1545.
  172. Sweetenham J.W. et al. Adult Burkitt’s and Burkitt-like non-Hodgkin’s lymphoma - Outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse: Results from the European group for blood and marrow transplantation // Journal of Clinical Oncology. American Society of Clinical Oncology, 1996. Vol. 14, № 9. P. 2465–2472.
  173. Mounier N. et al. Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II lymphoma study Association trial // Haematologica. 2013. Vol. 98, № 11. P. 1726–1731.
  174. Vacirca J.L. et al. Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma // Ann Hematol. 2014. Vol. 93, № 3. P. 403–409.
  175. Ohmachi K. et al. Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma // Journal of Clinical Oncology. American Society of Clinical Oncology, 2013. Vol. 31, № 17. P. 2103–2109.
  176. Chao N.J., Rosenberg S.A., Horning S.J. CEPP(B): An effective and well-tolerated regimen in poor-risk, aggressive non-Hodgkin’s lymphoma // Blood. 1990. Vol. 76, № 7. P. 1293–1298.
  177. Gopal A.K. et al. Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: A prospective multi-center phase II study by the Puget Sound Oncology Consortium // Leuk Lymphoma. 2010. Vol. 51, № 8. P. 1523–1529.
  178. Papageorgiou E.S. et al. Combination chemotherapy with gemcitabine and vinorelbine in the treatment of relapsed or refractory diffuse large B-cell lymphoma: A phase-II trial by the Hellenic Cooperative Oncology Group // Eur J Haematol. 2005. Vol. 75, № 2. P. 124–129.
  179. Sehn L.H. et al. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma // J Clin Oncol. J Clin Oncol, 2020. Vol. 38, № 2. P. 155–165.
  180. Goy A. et al. Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL // Blood. Blood, 2019. Vol. 134, № 13. P. 1024–1036.
  181. Armand P. et al. Pembrolizumab in relapsed or refractory primary mediastinal large b-cell lymphoma // Journal of Clinical Oncology. American Society of Clinical Oncology, 2019. Vol. 37, № 34. P. 3291–3299.
  182. McLaughlin P. et al. Chemotherapy with dexamethasone, high-dose cytarabine, and cisplatin for parenchymal brain lymphoma. // J Natl Cancer Inst. 1988. Vol. 80, № 17. P. 1408–1412.
  183. Welch M.R. et al. Autologous stem cell transplant in recurrent or refractory primary or secondary central nervous system lymphoma using thiotepa, busulfan and cyclophosphamide // Leuk Lymphoma. Informa Healthcare, 2015. Vol. 56, № 2. P. 361–367.
  184. Nguyen P.L. et al. Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma // Journal of Clinical Oncology. 2005. Vol. 23, № 7. P. 1507–1513.
  185. Michael J. Dickinson Wróbel T. et al. Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. 2022. P. 2220–2231.
  186. Hutchings M. et al. Glofitamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma: Extended Follow-Up from a Pivotal Phase II Study and Subgroup Analyses in Patients with Prior Chimeric Antigen Receptor T-Cell Therapy and by Baseline Total Metabolic Tumor Volume // Blood. 2023. Vol. 142, № Supplement 1.
  187. Abramson J, et al. Glofitamab plus Gemcitabine and Oxaliplatin (Glofit-GemOx) for Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results of a Global Randomized Phase III trial (STARGLO). Presented at: EHA Hybrid Congress; 2024 Jun 3-16. Abstract #LB3438
  188. Hopfinger G., Worel N. CAR T-cell therapy in diffuse large B-cell lymphoma // Memo - Magazine of European Medical Oncology. 2020. Vol. 13, № 1.
  189. Al-Mansour M., Al-Foheidi M., Ibrahim E. Efficacy and safety of second-generation CAR T-cell therapy in diffuse large B-cell lymphoma: A meta-analysis // Mol Clin Oncol. 2020. Vol. 13, № 4.
  190. Yamauchi N., Maruyama D. Current development of chimeric antigen receptor T-cell therapy for diffuse large B-cell lymphoma and high-grade B-cell lymphoma // European Journal of Haematology. 2024. Vol. 112, № 5.
  191. Zhou W. et al. Benefits of Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma // Front Genet. 2022. Vol. 12.
  192. Locke F.L. et al. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma // New England Journal of Medicine. 2022. Vol. 386, № 7.
  193. Kamdar M. et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial // The Lancet. 2022. Vol. 399, № 10343.
  194. Котомина Т.С. et al. Лимфома Беркитта и беременность. Возможности современной медицины // РМЖ. Мать и дитя. 2020. Vol. 3. P. 211–216.
  195. Dunleavy K., McLintock C. How I treat lymphoma in pregnancy // Blood. American Society of Hematology, 2020. Vol. 136, № 19. P. 2118–2124.
  196. Evens A.M. et al. Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis // J Clin Oncol. J Clin Oncol, 2013. Vol. 31, № 32. P. 4132–4139.
  197. Mazonakis M. et al. Radiotherapy of Hodgkin’s disease in early pregnancy: embryo dose measurements // Radiother Oncol. Radiother Oncol, 2003. Vol. 66, № 3. P. 333–339.
  198. Manuck T.A. et al. Preterm neonatal morbidity and mortality by gestational age: a contemporary cohort // Am J Obstet Gynecol. Am J Obstet Gynecol, 2016. Vol. 215, № 1. P. 103.e1-103.e14.
  199. Pinnix C.C. et al. The Management of Lymphoma in the Setting of Pregnancy // Curr Hematol Malig Rep. Curr Hematol Malig Rep, 2017. Vol. 12, № 3. P. 251–256.
  200. Amant F. et al. Pediatric Outcome after Maternal Cancer Diagnosed during Pregnancy // N Engl J Med. N Engl J Med, 2015. Vol. 373, № 19. P. 1824–1834.
  201. Дудина Г.А., Пивник А.В. Неходжкинские лимфомы у больных ВИЧ-инфекцией // Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний; под ред. И.В. Поддубной, В.Г. Савченко. 2018. P. 126–137.
  202. Cheson B.D. et al. Revised response criteria for malignant lymphoma // Journal of Clinical Oncology. 2007. Vol. 25, № 5. P. 579–586.
  203. Барях Е.А., Мякова Н.В., Поддубная И.В. Профилактика и лечение синдрома лизиса опухоли // Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний; под ред. И.В. Поддубной, В.Г. Савченко. 2018. P. 251–253.
  204. Барях Е.А. et al. Лейкоз/лимфома Беркитта: клинические особенности, диагностические критерии, терапевтическая тактика // Клиническая онкогематология. Фундаментальные исследования и клиническая практика. 2010. Vol. 3, № 2. P. 138–143.
  205. Narum S., Westergren T., Klemp M. Corticosteroids and risk of gastrointestinal bleeding: A systematic review and meta-analysis // BMJ Open. 2014. Vol. 4, № 5. P. e004587.
  206. Burget D.W., Chiverton S.G., Hunt R.H. Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression // Gastroenterology. Gastroenterology, 1990. Vol. 99, № 2. P. 345–351.
  207. Ивашкин В.Т. et al. Диагностика и лечение язвенной болезни у взрослых (Клинические рекомендации Российской гастроэнтерологической ассоциации, Российского общества колоректальных хирургов и Российского эндоскопического общества). // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020. Vol. 30, № 1. P. 49–70.
  208. Scally B. et al. Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials // Lancet Gastroenterol Hepatol. Elsevier Ltd, 2018. Vol. 3, № 4. P. 231–241.
  209. Владимирова Л.Ю. et al. Практические рекомендации по профилактике и лечению тошноты и рвоты у онкологических больных // Злокачественные опухоли: Практические рекомендации RUSSCO. 2022. Vol. 12, № 3S2. P. 26–39.
  210. Navari R.M., Gray S.E., Kerr A.C. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial // J Support Oncol. J Support Oncol, 2011. Vol. 9, № 5. P. 188–195.
  211. Navari R.M., Aapro M. Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting // New England Journal of Medicine. New England Journal of Medicine (NEJM/MMS), 2016. Vol. 374, № 14. P. 1356–1367.
  212. Roy V. et al. Hematopoietic Growth Factors. NCCN Guidelines. Ver 1.2022. 2022.
  213. Neumann S. et al. Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DG // Annals of Hematology. Ann Hematol, 2013. Vol. 92, № 4. P. 433–442.
  214. Spirin M., Galstyan G., Drokov M. Central venous access in lymphoma patients (pts) with superior vena cava syndrome (SVCS) // Intensive Care Medicine E[perimental. 2019. Vol. 7, № Suppl. 3:001341. P. 388–389.
  215. Константинова Т.С., Клясова Г.А., Капланов К.Д. Лечение и профилактика инфекционных осложнений у пациентов с лимфопролиферативными заболеваниями. // Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний; под ред. И.В. Поддубной, В.Г. Савченко. 2018. P. 289–311.
  216. Сомонова О.В. et al. Практические рекомендации по профилактике и лечению тромбоэмболических осложнений у онкологических больных // Злокачественные опухоли: Практические рекомендации RUSSCO. 2021. Vol. 11, № 3S2. P. 47.
  217. Lyman G.H. et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer // Blood Adv. Blood Adv, 2021. Vol. 5, № 4. P. 927–974.
  218. Семиглазова Т.Ю. et al. Практические рекомендации по лечению и профилактике мукозитов // Злокачественные опухоли: Практические рекомендации RUSSCO. 2021. Vol. 11, № 3s2. P. 51.
  219. Peterson D.E., Bensadoun R.J., Roila F. Management of oral and gastrointestinal mucositis: ESMO Clinical Practice Guidelines // Ann Oncol. Ann Oncol, 2011. Vol. 22 Suppl 6, № Suppl 6.
  220. Сытов А.В. et al. Практические рекомендации по нутритивной поддержке онкологических больных // RUSSCO. 2017. P. 524–532.
  221. de van der Schueren M.A.E. et al. Systematic review and meta-analysis of the evidence for oral nutritional intervention on nutritional and clinical outcomes during chemo(radio)therapy: current evidence and guidance for design of future trials // Ann Oncol. Ann Oncol, 2018. Vol. 29, № 5. P. 1141–1153.
  222. Oktay K. et al. Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update // J Clin Oncol. J Clin Oncol, 2018. Vol. 36, № 19. P. 1994–2001.
  223. Meirow D., Nugent D. The effects of radiotherapy and chemotherapy on female reproduction // Hum Reprod Update. 2001. Vol. 7, № 6. P. 535–543.
  224. Paul K.L. Rehabilitation and exercise considerations in hematologic malignancies. // Am J Phys Med Rehabil. 2011. Vol. 90, № 5 Suppl 1. P. S88-94.
  225. Rozental A. et al. The role of maintenance therapy in patients with diffuse large B cell lymphoma: A systematic review and meta-analysis // Hematol Oncol. John Wiley and Sons Ltd, 2019. Vol. 37, № 1. P. 27–34.
  226. Румянцев А.Г., Самочатова Е.В. Практическое руководство по детским болезням. Том 4. Гематология и онкология детского возраста / ed. Коколина В.Ф., Румянцев А.Г. Медпрактика-М., 2004. 792 p.
  227. Cheson B.D. et al. Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-hodgkin lymphoma: The lugano classification // Journal of Clinical Oncology. American Society of Clinical Oncology, 2014. Vol. 32, № 27. P. 3059–3067.
  228. A Predictive Model for Aggressive Non-Hodgkin’s Lymphoma // New England Journal of Medicine. 1993. Vol. 329, № 14. P. 987–994.
  229. Abdelhamid T. et al. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: A retrospective study // J Egypt Natl Canc Inst. 2011. Vol. 23, № 1. P. 17–24.
  230. Meignan M., Gallamini A., Haioun C. Report on the First International Workshop on interim-PET scan in lymphoma // Leukemia and Lymphoma. 2009. Vol. 50, № 8. P. 1257–1260.
  231. Abrey L.E. et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma // Journal of Clinical Oncology. 2005. Vol. 23, № 22. P. 5034–5043.
  232. Fan E., Brodie D., Slutsky A.S. Acute respiratory distress syndrome advances in diagnosis and treatment // JAMA - Journal of the American Medical Association. American Medical Association, 2018. Vol. 319, № 7. P. 698–710.
  233. Young P. et al. Effect of a buffered crystalloid solution vs saline on acute kidney injury among patients in the intensive care unit: The SPLIT randomized clinical trial // JAMA - Journal of the American Medical Association. American Medical Association, 2015. Vol. 314, № 16. P. 1701–1710.
  234. Hoorn E.J. Intravenous fluids: balancing solutions // Journal of Nephrology. Springer New York LLC, 2017. Vol. 30, № 4. P. 485–492.
  235. Криволапов Ю.А. Технические аспекты выполнения трепанобиопсий костного мозга. Клиническая онкогематология 2014; 7:290—295 // Клиническая онкогематология. 2014. Vol. 7. P. 290–295.
  236. Wang J. et al. Diagnostic utility of bilateral bone marrow examination: Significance of morphologic and ancillary technique study in malignancy // Cancer. Cancer, 2002. Vol. 94, № 5. P. 1522–1531.
  237. Pluschnig U. et al. Extravasation emergencies: state-of-the-art management and progress in clinical research. // Memo. Springer, 2016. Vol. 9, № 4. P. 226–230.
  238. Zeidler K. et al. Optimal preprocedural platelet transfusion threshold for central venous catheter insertions in patients with thrombocytopenia. // Transfusion (Paris). 2011. Vol. 51, № 11. P. 2269–2276.
  239. Zerati A.E. et al. Totally implantable venous catheters : history , implantation technique and complications. // J Vasc Bras. 2017. Vol. 16, № 2. P. 128–139.
  240. Gow K.W., Tapper D., Hickman R.O. Between the lines: The 50th anniversary of long-term central venous catheters // Am J Surg. Elsevier Ltd, 2017. Vol. 213, № 5. P. 837–848.
  241. Yeral M. et al. Tunnelled central venous catheter-related problems in the early phase of haematopoietic stem cell transplantation and effects on transplant outcome. // Turk J Haematol. Galenos Yayinevi, 2015. Vol. 32, № 1. P. 51–57.
  242. Maki D.G., Kluger D.M., Crnich C.J. The Risk of Bloodstream Infection in Adults With Different Intravascular Devices: A Systematic Review of 200 Published Prospective Studies // Mayo Clin Proc. Elsevier, 2006. Vol. 81, № 9. P. 1159–1171.
  243. Hamilton H. Central Venous Catheters / ed. Bodenham A.R. Oxford, UK: Wiley-Blackwell, 2009.
  244. Biffi R. Introduction and Overview of PICC History // Peripherally Inserted Central Venous Catheters. Milano: Springer Milan, 2014. P. 1–6.
  245. Linenberger M.L. Catheter-related thrombosis: risks, diagnosis, and management. // J Natl Compr Canc Netw. 2006. Vol. 4, № 9. P. 889–901.
  246. Lee A.Y.Y., Kamphuisen P.W. Epidemiology and prevention of catheter-related thrombosis in patients with cancer // Journal of Thrombosis and Haemostasis. 2012. № 10. P. 1491–1499.
  247. Цепенщинков Л.В., Лядов В.К. Периферически имплантируемый центральный венозный катетер: обзор литераутры. // Клиническая онкогематология. 2014. Vol. 7, № 2. P. 220–228.
  248. Linder L.E. et al. Material thrombogenicity in central venous catheterization: a comparison between soft, antebrachial catheters of silicone elastomer and polyurethane. // JPEN J Parenter Enteral Nutr. 1984. Vol. 8, № 4. P. 399–406.
  249. Watters V.A., Grant J.P. Use of Electrocardiogram to Position Right Atrial Catheters During Surgery // Ann Surg. Vol. 225, № 2. P. 165–171.
  250. Taal M.W., Chesterton L.J., McIntyre C.W. Venography at insertion of tunnelled internal jugular vein dialysis catheters reveals significant occult stenosis // Nephrology Dialysis Transplantation. Oxford University Press, 2004. Vol. 19, № 6. P. 1542–1545.
  251. Lobato E.B. et al. Cross-sectional area of the right and left internal jugular veins. // J Cardiothorac Vasc Anesth. 1999. Vol. 13, № 2. P. 136–138.
  252. Червонцева А.М. Повреждение сосудистого эндотелия в процессе лечения острых миелоидных лейкозов. 2008.
  253. Багирова Н.С. Инфекции, связанные с внутрисосудистыми устройствами: терминология, диагностика, профилактика и терапия // Злокачественные опухоли. 2014. № 3. P. 164–171.
  254. Bannon M.P., Heller S.F., Rivera M. Anatomic considerations for central venous cannulation. // Risk Manag Healthc Policy. Dove Press, 2011. Vol. 4. P. 27–39.
  255. Milling T.J. et al. Randomized, controlled clinical trial of point-of-care limited ultrasonography assistance of central venous cannulation: The Third Sonography Outcomes Assessment Program (SOAP-3) Trial* // Crit Care Med. 2005. Vol. 33, № 8. P. 1764–1769.
  256. Воробьев А.И. et al. Критические состояния при гемобластозах (типичные формы и выживаемость в условиях отделения реанимации). // Терапевтический архив. 1993. Vol. 65, № 7. P. 3–6.
  257. Галстян Г.М., Городецкий В.М. Опыт работы отделения реанимации и интенсивной терапии ФГБУ ГНЦ МЗиСР РФ // Клиническая онкогематология. 2011. Vol. 4, № 1. P. 75–78.
  258. Lamia B. et al. Changes in severity and organ failure scores as prognostic factors in onco-hematological malignancy patients admitted to the ICU // Intensive Care Med. Intensive Care Med, 2006. Vol. 32, № 10. P. 1560–1568.
  259. Evison J.M. et al. Intensive care unit admission in patients with haematological disease: incidence, outcome and prognostic factors. 2001.
  260. Silfvast T. et al. Multiple organ failure and outcome of critically ill patients with haematological malignancy // Acta Anaesthesiol Scand. Acta Anaesthesiol Scand, 2003. Vol. 47, № 3. P. 301–306.
  261. Benoit D.D. et al. Outcome and early prognostic indicators in patients with a hematologic malignancy admitted to the intensive care unit for a life-threatening complication // Crit Care Med. Crit Care Med, 2003. Vol. 31, № 1. P. 104–112.
  262. Schellongowski P. et al. Prognostic factors for intensive care unit admission, intensive care outcome, and post-intensive care survival in patients with de novo acute myeloid leukemia: a single center experience // Haematologica. 2011. Vol. 96, № 2. P. 231–237.
  263. Medić M.G. et al. Hematologic malignancies in the medical intensive care unit – Outcomes and prognostic factors // Hematology. Maney Publishing, 2015. Vol. 20, № 5. P. 247–253.
  264. Jackson K. et al. Outcomes and prognostic factors for patients with acute myeloid leukemia admitted to the intensive care unit // Leuk Lymphoma. Leuk Lymphoma, 2013. Vol. 55, № April. P. 1–8.
  265. Ahmed T. et al. Outcomes and changes in code status of patients with acute myeloid leukemia undergoing induction chemotherapy who were transferred to the intensive care unit // Leuk Res. Elsevier Ltd, 2017. Vol. 62. P. 51–55.
  266. Yelvington B.J. Subcutaneous Rituximab in Follicular Lymphoma, Chronic Lymphocytic Leukemia, and Diffuse Large B-Cell Lymphoma. // J Adv Pract Oncol. Harborside Press, 2018. Vol. 9, № 5. P. 530–534.
  267. Davies A. et al. Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development // Advances in Therapy. Springer Healthcare, 2017. Vol. 34, № 10. P. 2210–2231.
  268. García‐Muñoz R. et al. Safety of switching from intravenous to subcutaneous rituximab during first‐line treatment of patients with non‐Hodgkin lymphoma: the Spanish population of the MabRella study // Br J Haematol. Blackwell Publishing Ltd, 2020. Vol. 188, № 5. P. 661–673.
  269. Macdonald D. et al. A canadian perspective on the subcutaneous administration of rituximab in non-Hodgkin lymphoma // Current Oncology. Multimed Inc., 2017. Vol. 24, № 1. P. 33–39.
  270. Gang A.O. et al. R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group. // Ann Oncol. 2012. Vol. 23, № 1. P. 147–153.
  271. Raefsky E.L. et al. Brief duration rituximab(R)/chemotherapy (CNOP or CVP) followed by maintenance rituximab in elderly/poor performance status patients (pts) with diffuse large B-cell lymphoma (DLBCL): A phase II trial of the Minnie Pearl Cancer Research Network // Journal of Clinical Oncology. American Society of Clinical Oncology, 2006. Vol. 24, № 18_suppl. P. 7577–7577.
  272. Thomas D.A. et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia // Cancer. Cancer, 2006. Vol. 106, № 7. P. 1569–1580.
  273. Batchelor T. et al. Treatment of Primary CNS Lymphoma With Methotrexate and Deferred Radiotherapy: A Report of NABTT 96–07 // Journal of Clinical Oncology. American Society of Clinical Oncology, 2003. Vol. 21, № 6. P. 1044–1049.
  274. Zhu J.-J. et al. High-dose methotrexate for elderly patients with primary CNS lymphoma // Neuro Oncol. Oxford University Press (OUP), 2009. Vol. 11, № 2. P. 211–215.
  275. Samochatova E. V. et al. Therapy of advanced-stage mature b-cell lymphoma and leukemia in children and adolescents with rituximab and reduced intensity induction chemotherapy (B-NHL 2004M protocol): The results of a multicenter study // J Pediatr Hematol Oncol. Lippincott Williams and Wilkins, 2014. Vol. 36, № 5. P. 395–401.
  276. Krause D.S. et al. CD34: Structure, biology, and clinical utility // Blood. American Society of Hematology, 1996. Vol. 87, № 1. P. 1–13
  277. Giralt S. et al. Optimizing autologous stem cell mobilization strategies to improve patient outcomes: Consensus guidelines and recommendations // Biology of Blood and Marrow Transplantation. Elsevier, 2014. Vol. 20, № 3. P. 295–308.
  278. Stiff P.J. et al. Transplanted CD34 + Cell Dose Is Associated with Long-Term Platelet Count Recovery following Autologous Peripheral Blood Stem Cell Transplant in Patients with Non-Hodgkin Lymphoma or Multiple Myeloma // Biology of Blood and Marrow Transplantation. Biol Blood Marrow Transplant, 2011. Vol. 17, № 8. P. 1146–1153.
  279. Passos-Coelho J.L. et al. Predictive factors for peripheral-blood progenitor-cell collections using a single large-volume leukapheresis after cyclophosphamide and granulocyte- macrophage colony-stimulating factor mobilization // Journal of Clinical Oncology. American Society of Clinical Oncology, 1995. Vol. 13, № 3. P. 705–714.
  280. Hohaus S. et al. Successful autografting following myeloablative conditioning therapy with blood stem cells mobilized by chemotherapy plus rhG-CSF. // Exp Hematol. 1993. Vol. 21, № 4. P. 508–514.
  281. Покровская О.С. et al. Мобилизация гемопоэтических клеток крови у больных миеломной болезнью // Проблемы гематологии и переливания. 2003. P. 55–56.
  282. Olivieri A. et al. Proposed definition of “poor mobilizer” in lymphoma and multiple myeloma: An analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo // Bone Marrow Transplant. Bone Marrow Transplant, 2012. Vol. 47, № 3. P. 342–351.
  283. Yang B.B., Kido A. Pharmacokinetics and pharmacodynamics of pegfilgrastim // Clinical Pharmacokinetics. Clin Pharmacokinet, 2011. Vol. 50, № 5. P. 295–306.
  284. Costa L.J. et al. Pegfilgrastim-versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: Efficacy and cost analysis // Transfusion (Paris). Transfusion, 2012. Vol. 52, № 11. P. 2375–2381.
  285. Dale D.C. et al. A systematic literature review of the efficacy, effectiveness, and safety of filgrastim // Supportive Care in Cancer. Springer Verlag, 2018. Vol. 26, № 1. P. 7–20.
  286. Smith T.J. et al. Recommendations for the use of WBC growth factors: American society of clinical oncology clinical practice guideline update // Journal of Clinical Oncology. American Society of Clinical Oncology, 2015. Vol. 33, № 28. P. 3199–3212.
  287. Bilgin Y.M., De Greef G.E. Plerixafor for stem cell mobilization: The current status // Current Opinion in Hematology. Lippincott Williams and Wilkins, 2016. Vol. 23, № 1. P. 67–71.
  288. Покровская О.С. Кроветворная ткань и стромальное микроокружение в процессе интенсивной терапии и мобилизации гемопоэтических стволовых клеток у больных множественной миеломой: Автореф. дис.канд.мед.наук. 2011. Vol. 153. 29 p.
  289. Афанасьева О.И., Воинов В.А., Гольдфарб Ю.С. Экстракорпоральная гемокоррекция: терминология, языковые соответствия. СПб, 2016. P. 7–15.
  290. Ikeda K. et al. Adverse Events Associated With Infusion of Hematopoietic Stem Cell Products: A Prospective and Multicenter Surveillance Study // Transfusion Medicine Reviews. W.B. Saunders, 2018. Vol. 32, № 3. P. 186–194.
  291. Sutherland D.R. et al. The ISHAGE guidelines for CD34+ cell determination by flow cytometry // Journal of Hematotherapy and Stem Cell Research. J Hematother, 1996. Vol. 5, № 3. P. 213–226.
  292. Enric Carreras D.C., Mohty Mohamad K.N. Hematopoietic Stem Cell Transplantation and Cellular Therapies. 2019. 702 p.
  293. Frankiewicz A. et al. Comparable safety profile of BeEAM (bendamustine, etoposide, cytarabine, melphalan) and BEAM (carmustine, etoposide, cytarabine, melphalan) as conditioning before autologous haematopoietic cell transplantation. // Contemp Oncol (Pozn). Termedia Publishing, 2018. Vol. 22, № 2. P. 113–117.
  294. Caballero M.D. et al. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors // Bone Marrow Transplant. Bone Marrow Transplant, 1997. Vol. 20, № 6.
  295. Mills W. et al. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin’s lymphoma. // J Clin Oncol. J Clin Oncol, 1995. Vol. 13, № 3. P. 588–595.
  296. Colita A. et al. LEAM vs. BEAM vs. CLV Conditioning Regimen for Autologous Stem Cell Transplantation in Malignant Lymphomas. Retrospective Comparison of Toxicity and Efficacy on 222 Patients in the First 100 Days After Transplant, On Behalf of the Romanian Society for Bon // Front Oncol. Front Oncol, 2019. Vol. 9. P. 892.
  297. Sharma A. et al. Comparison of BEAM vs. LEAM regimen in autologous transplant for lymphoma at AIIMS. // Springerplus. Springerplus, 2013. Vol. 2. P. 489.
  298. Perz J.B. et al. LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin’s lymphoma: treatment outcome and risk factor analysis in 67 patients from a single centre. // Bone Marrow Transplant. Bone Marrow Transplant, 2007. Vol. 39, № 1. P. 41–47.
  299. Ramzi M. et al. Autologous noncryopreserved hematopoietic stem cell transplant with CEAM as a modified conditioning regimen in patients with Hodgkin lymphoma: a single-center experience with a new protocol. // Exp Clin Transplant. Exp Clin Transplant, 2012. Vol. 10, № 2. P. 163–167.
  300. Visani G. et al. XRCC1 399GG genotype predicts significantly longer overall survival in resistant lymphoma patients treated with Benda-EAM and ASCT // Bone Marrow Transplant. Nature Publishing Group, 2020. Vol. 55, № 4. P. 818–820.
  301. Visani G. et al. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. // Blood. 2011. Vol. 118, № 12. P. 3419–3425.
  302. DeFilipp Z. et al. High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission. // Cancer. Cancer, 2017. Vol. 123, № 16. P. 3073–3079.
  303. Conn H.O., Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. // J Intern Med. J Intern Med, 1994. Vol. 236, № 6. P. 619–632.304.
  304. Hu Z.-H. et al. Efficacy of proton pump inhibitors for patients with duodenal ulcers: A pairwise and network meta-analysis of randomized controlled trials // Saudi Journal of Gastroenterology. Medknow Publications, 2017. Vol. 23, № 1. P. 11.
  305. Lanas A., Chan F.K.L. Peptic ulcer disease. // Lancet. Lancet, 2017. Vol. 390, № 10094. P. 613–624.
  306. Auner H.W. et al. Infectious complications after autologous hematopoietic stem cell transplantation: Comparison of patients with acute myeloid leukemia, malignant lymphoma, and multiple myeloma // Ann Hematol. Ann Hematol, 2002. Vol. 81, № 7. P. 374–377.
  307. Gil L., Styczynski J., Komarnicki M. Infectious complication in 314 patients after high-dose therapy and autologous hematopoietic stem cell transplantation: Risk factors analysis and outcome // Infection. Infection, 2007. Vol. 35, № 6. P. 421–427.
  308. Eleutherakis-Papaiakovou E. et al. Prophylactic antibiotics for the prevention of neutropenic fever in patients undergoing autologous stem-cell transplantation: Results of a single institution, randomized phase 2 trial // Am J Hematol. Am J Hematol, 2010. Vol. 85, № 11. P. 863–867.
  309. Moghnieh R. et al. Bacteraemia post-autologous haematopoietic stem cell transplantation in the absence of antibacterial prophylaxis: a decade’s experience from Lebanon // Infection. Urban und Vogel GmbH, 2018. Vol. 46, № 6.
  310. Клясова Г.А. et al. Эмпирическая антимикробная терапия у больных острыми лейкозами: итоги многоцентрового исследования // Терапевтический архив. 1998. Vol. 70, № 7. P. 15–21.
  311. Савченко В.Г. и др. Алгоритмы диагностики и протоколы лечения заболеваний системы крови. Москва: Практика, 2018. 1008 p.
  312. Terpos E. et al. European myeloma network guidelines for the management of multiple myeloma-related complications // Haematologica. Ferrata Storti Foundation, 2015. Vol. 100, № 10. P. 1254–1266.
  313. Maertens J. et al. ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients // Journal of Antimicrobial Chemotherapy. Oxford University Press, 2016. Vol. 71, № 9. P. 1–8.
  314. Virizuela J.A. et al. Nutritional support and parenteral nutrition in cancer patients: an expert consensus report // Clinical and Translational Oncology. Springer-Verlag Italia s.r.l., 2018. Vol. 20, № 5. P. 619–629.
  315. Бесова Н.С. et al. Клинические рекомендации по нутритивной поддержке при химиотерапии и/или лучевой терапии. 2014.
  316. Arends J. et al. ESPEN guidelines on nutrition in cancer patients // Clinical Nutrition. Churchill Livingstone, 2017. Vol. 36, № 1. P. 11–48.
  317. Camblor-Álvarez M. et al. Soporte nutricional y nutrición parenteral en el paciente oncológico: informe de consenso de un grupo de expertos // Nutr Hosp. ARAN Ediciones, 2018. Vol. 35, № 1.
  318. Baiu I., Spain D.A. Parenteral Nutrition // JAMA - Journal of the American Medical Association. American Medical Association, 2019. Vol. 321, № 21. P. 2142.
  319. Oken M.M. et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group // Am J Clin Oncol. 1982. Vol. 5, № 6. P. 649–655.
  320. Khorana A. et al. Development and validation of a predictive model for chemotherapy- associated thrombosis // Blood. 2008. Vol. 111, № 10. P. 4902–4907.
  321. Wang X. et al. Decreased lymphoma-related deaths and improved long-term relative survival with radiotherapy for early-stage diffuse large B-cell lymphoma in the rituximab era //Radiotherapy and Oncology. 2023. Vol.188. P. 109902.
  322. Jegadeesh N. et al. Predictors of local recurrence after rituximab-based chemotherapy alone in stage III and IV diffuse large B-cell lymphoma: guiding decisions for consolidative radiation //International Journal of Radiation Oncology* Biology* Physics. 2015. Vol.92, № 1. P. 107-112.
  323. Mikhaeel N. G. et al. The optimal use of imaging in radiation therapy for lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group (ILROG) //International Journal of Radiation Oncology* Biology* Physics. 2019. Vol.104, № 3. P. 501-512.
  324. Ng A. K. et al. Role of radiation therapy in patients with relapsed/refractory diffuse large B-cell lymphoma: guidelines from the International Lymphoma Radiation Oncology Group //International Journal of Radiation Oncology* Biology* Physics. 2018. Vol.100 , № 3. P. 652-669.
  325. Yu Q. et al. Radiation prior to chimeric antigen receptor T-cell therapy is an optimizing bridging strategy in relapsed/refractory aggressive B-cell lymphoma //Radiotherapy and Oncology. 2022. Vol.177. P. 53-60.
  326. Dabaja B. S. et al. Making every single gray count: involved site radiation therapy delineation guidelines for hematological malignancies //International Journal of Radiation Oncology, Biology, Physics. 2020. Vol.106, № 2. P. 279-281.
  327. Hoppe B. S. et al. Involved-field radiotherapy before high-dose therapy and autologous stem-cell rescue in diffuse large-cell lymphoma: long-term disease control and toxicity //Journal of clinical oncology. 2008. Vol.26, № 11. P. 1858-1864.
  328. Petersen P. M. et al. Prospective phase II trial of image-guided radiotherapy in Hodgkin lymphoma: benefit of deep inspiration breath-hold //Acta Oncologica. 2015. Vol.54, № 1. P. 60-66.
  329. Marks L. B. et al. Use of normal tissue complication probability models in the clinic //International Journal of Radiation Oncology* Biology* Physics. 2010. Vol.76, № 3. P. S10-S19.
  330. Yang B.B., Kido A. Pharmacokinetics and pharmacodynamics of pegfilgrastim // Clinical Pharmacokinetics. Clin Pharmacokinet, 2011. Vol. 50, № 5. P. 295–306.
  331. A Dodero, A Guidetti Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma. Leukemia. 2019 Apr;33(4):1047-1051. doi: 10.1038/s41375-018-0320-9. Epub 2019 Jan 10.
  332. Мангасарова Я. К. et al. Ответ-адаптированная стратегия терапии первичной медиастинальной В-крупноклеточной лимфомы: результаты проспективного одноцентрового клинического исследования // Клиническая онкогематология. 2024. № 4 (17). C. 335–346.
  333. Emanuele Zucca, et al Observation vs. radiotherapy in primary mediastinal B-cell lymphoma patients with complete response to standard immunochemotherapy: The IELSG37 randomized trial. Journal of Clinical Oncology Volume 41, Number 17_suppl https://doi.org/10.1200/JCO.2023.41.17_suppl.LBA7505
  334. J.Shen, J.Liu . Bruton’s tyrosine kinase inhibitors in the treatment of primary central nervous system lymphoma: A mini-review Front. Oncol., 17 November 2022 Sec. Neuro-Oncology and Neurosurgical Oncology Volume 12 - 2022 | https://doi.org/10.3389/fonc.2022.1034668
  335. NCCN Clinical Practice Guidelines in Oncology B-Cell Lymphomas Version 3. 2024 — October 10, 2024
  336. Fabian Knörr , Martin Zimmermann , Andishe Attarbaschi et al, Dose-adjusted EPOCH-rituximab or intensified B-non-Hodgkin lymphoma therapy for pediatric primary mediastinal large B-cell lymphoma. Results from the study B-NHL-BFM-04 and the NHL-BFM registry 2012 Haematologica. 2021 Sep 9;106(12):3232–3235. doi: 10.3324/haematol.2021.278971
  337. Huang G, Huang J, Zhang Z, Xue C, Liu Y. Nivolumab plus gemcitabine, dexamethasone, and cisplatin chemotherapy induce durable complete remission in relapsed/refractory primary mediastinal B-cell lymphoma: a case report and literature review. J Int Med Res. 2020 Aug;48(8):300060520945075. doi: 10.1177/0300060520945075. PMID: 32783492; PMCID: PMC7425276.
  338. Xue Y, Gao S, Gou J, Yin T, He H, Wang Y, Zhang Y, Tang X, Wu R. Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action. Expert Opin Drug Deliv. 2021 Feb;18(2):187-203. doi: 10.1080/17425247.2021.1825376. Epub 2020 Oct 5. PMID: 32954856.
  339. Современные принципы ведения беременности у пациенток с лимфомами / Р. Г. Шмаков, А. И. Ахмедова, Е. С. Полушкина [и др.] // Акушерство и гинекология. – 2019. – № 7. – С. 40-48. – DOI 10.18565/aig.2019.7.40-48. – EDN LEWTUM.
  340. Wolters V, Heimovaara J, Maggen C, Cardonick E, Boere I, Lenaerts L, Amant F. Management of pregnancy in women with cancer. Int J Gynecol Cancer. 2021 Mar;31(3):314-322. doi: 10.1136/ijgc-2020-001776. PMID: 33649001; PMCID: PMC7925815.
  341. de Haan J, Verheecke M, Van Calsteren K, Van Calster B, Shmakov RG, Mhallem Gziri M, Halaska MJ, Fruscio R, Lok CAR, Boere IA, Zola P, Ottevanger PB, de Groot CJM, Peccatori FA, Dahl Steffensen K, Cardonick EH, Polushkina E, Rob L, Ceppi L, Sukhikh GT, Han SN, Amant F; International Network on Cancer and Infertility Pregnancy (INCIP). Oncological management and obstetric and neonatal outcomes for women diagnosed with cancer during pregnancy: a 20-year international cohort study of 1170 patients. Lancet Oncol. 2018 Mar;19(3):337-346. doi: 10.1016/S1470-2045(18)30059-7. Epub 2018 Jan 26. Erratum in: Lancet Oncol. 2021 Sep;22(9):e389. doi: 10.1016/S1470-2045(21)00475-7. PMID: 29395867.
  342. Федорова Л. В., Лепик К. В., Коцелябина П. В., Кондакова Е. В., Попова М. О., Борзенкова Е. С., Байков В. В., Моисеев И. С., Михайлова Н. Б., Кулагин А. Д. СРАВНЕНИЕ ЭФФЕКТИВНОСТИ ТЕРАПИИ НИВОЛУМАБОМ В ДОЗЕ 40 МГ И 3 М Г/КГ У ПАЦИЕНТОВ С РЕФРАКТЕРНОЙ И РЕЦИДИВИРУЮЩЕЙ КЛАССИЧЕСКОЙ ЛИМФОМОЙ ХОДЖКИНА // Гематология и трансфузиология. 2022. №S
  343. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A Predictive Model for Aggressive Non-Hodgkin's Lymphoma.NEJM 1993, Sept 30, 329(14): 987-994.
  344. Marcia Torresan Delamain 1, Maria Gomes da Silva 2, Eliana Cristina Martins Miranda 3, Joana Desterro 2, Stefano Luminari 4, Anna Fedina 4, Francesco Merli 5, Carlos Sergio Chiattone 6, Katia Borgia Barbosa Pagnano 1, Massimo Federico 4, Carmino Antonio de Souza. Age-adjusted international prognostic index is a predictor of survival in gastric diffuse B-cell non-Hodgkin lymphoma patients. Rev Bras Hematol Hemoter . 2016 Jul-Sep;38(3):247-51. doi: 10.1016/j.bjhh.2016.04.010.
  345. R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma (HOVON/SAKK): final results of a multicentre, phase 3, open-label, randomised trial. Martine E D Chamuleau, Frank Stenner, Urban Novak, Monique C Minnema, Paul Geerts, MDj,ac∙ et al. The Lancet Dec 2023, Vol.10, Iss 12
  346. Wilson WH, Grossbard ML, Pittaluga S, et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: A pharmacodynamic approach with high efficacy. Blood. 2002;99:2685–2693. doi: 10.1182/blood.v99.8.2685.
  347. Протокол диагностики и лечения больных первичной тестикулярной лимфомой (ПТЛ). Королева Д.А., Щецова О.О., Габеева Н.Г., Звонков Е.Е. Алгоритмы диагностики и протоколы лечения заболеваний системы крови под редакцией Е.Н. Паровичниковой. 2024 год – Т2 – стр. 377-402 ИД «Практика» Москва.
  348. Протокол диагностики и лечения больных первичной диффузной В-крупноклеточной лимфомой молочной железы (ПДВККЛ МЖ). Королева Д.А., Щецова О.О., Габеева Н.Г., Звонков Е.Е. Алгоритмы диагностики и протоколы лечения заболеваний системы крови под редакцией Е.Н. Паровичниковой. 2024 год – Т2 – стр. 355-378 ИД «Практика» Москва.
  349. H Ghesquieres, M Chevrier, M Laadhari et al. Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA). Clinical Trial Ann Oncol. 2019 Apr 1;30(4):621-628. doi: 10.1093/annonc/mdz032.
  350. Justin T Low, Katherine B Peters. Ibrutinib in primary central nervous system diffuse large B-cell lymphoma. CNS Oncol. 2020 Mar 6;9(1): CNS51. doi: 10.2217/cns-2019-0022
  351. Jun Ho Yi MD, Seok Jin Kim, Sang A Kim et al. Nivolumab in Relapsed or Refractory Primary CNS Lymphoma: Multicenter, Retrospective Study Blood. Volume 142, Supplement 1, Page 1772. https://doi.org/10.1182/blood-2023-186554
  352. Д. А. Королева, Н. Г. Габеева, Г. М. Галстян, А. М. Ковригина, Г. А. Яцык, С. Ю. Федорова, Я. К. Мангасарова, Е. Е. Звонков. Успешное лечение рецидивов первичной медиастинальной В-крупноклеточной лимфомы с поражением центральной нервной системы. Гематология и трансфузиология. Том 68, № 3 (2023). https://doi.org/10.35754/0234-5730-2023-68-3-398-409
  353. Christopher Dittus, Roy Ervin Strowd III, Kelly Hoye et al. A Pilot Study Evaluating Acalabrutinib for the Treatment of Relapsed/Refractory Primary and Secondary Central Nervous System Lymphomas. Blood (2022) 140 (Supplement 1): 6616–6617. https://doi.org/10.1182/blood-2022-165139
  354. Lauren Schaff, Lakshmi Nayak &Christian Grommes. Bruton’s tyrosine kinase (BTK) inhibitors for the treatment of primary central nervous system lymphoma (PCNSL): current progress and latest advances. Leukemia & Lymphoma. Volume 65, 2024 - Issue 7 Pages 882-894. https://doi.org/10.1080/10428194.2024.2333985
  355. Khe Hoang-Xuan, Roch Houot, Carole Soussain et al. First Results of the Acsé Pembrolizumab Phase II in the Primary CNS Lymphoma (PCNSL). Blood. Volume 136, Supplement 1, 2020, Pages 15-16. https://doi.org/10.1182/blood-2020-141773
  356. Российские клинические рекомендации по диагностике и лечению лимфопролиферативных заболеваний под редакцией И.В.Поддубной, В.Г.Савченко 2018г
  357. Сидибе Н., Солодкий В.А., Сотников В.М. Непосредственные и отдаленные результаты химиолучевого лечения агрессивных нодальных неходжкинских лимфом брюшной полости и таза // Вопросы онкологии. 2022. Т. 68. № 3S. С. 136-137.
  358. Joachim Yahalom, Tim Illidge, Lena Specht, et al., Modern Radiation Therapy for Extranodal Lymphomas: Field and Dose Guidelines From the International Lymphoma Radiation Oncology Group//. Int J Radiation Oncol Biol Phys, 2015, Vol. 92, No. 1, pp. 11-31. http://dx.doi.org/10.1016/j.ijrobp.2015.01.009
  359. Трофимова О.П., Заводнова И.З., Тумян Г.С., Прямикова Ю.И., Волкова Н.В., Зайченко О.С., Назаренко А.В. Современная лучевая терапия в мультимодальном лечении больных первичной медиастинальной (тимической) В-крупноклеточной лимфомой (результаты лечения 131 больного в ФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России). // Современная онкология. – 2018. – Т. 20, №4. – С. 5-15.
  360. Виноградова Ю.Н., Рябчикова В.В., Чумаченко А.И., Карягина Е.В., Медведева Н.В., Лучинин А.С., Минаева Н.В., Шнейдер Т.В., Ходжибекова М.М., Iline Nicolas, Ильин Н.В. Особенности и результаты терапии больных первичной медиастинальной В-клеточной крупноклеточной лимфомой. // Практическая онкология. – 2021. – Т. 22, №1. – с. 59-71.
  361. Vikram Jairam, MD, Henry S. Park, James B. Yu, Ranjit S. Bindra, Joseph N. Contessa. Practice Patterns Related to Mitigation of Neurocognitive Decline in Patients Receiving Whole Brain Radiation Therapy //Advances in Radiation Oncology: July−August 2022, 7, P.1-5.
  362. N. Gleim A. Rühle ,, S. Heider , F. Nagler, F.A. Giordano , S.E. Combsf , J. Becker .Neuroprotection in radiotherapy of brain metastases: A pattern-of-care analysis in Germany, Austria and Switzerland by the German Society for radiation Oncology − working group Neuro-Radio-Oncology (DEGRO AG-NRO) // Сlinical and Translational Radiation Oncology,2024, V.47, P.1-8.
  363. Wright C.M. et al., Radiation Therapy for Relapsed or Refractory Diffuse Large B-Cell Lymphoma: What Is the Right Regimen for Palliation? // Advances in Radiation Oncology, 2022, V.7, P2-12 // https://doi.org/10.1016/j.adro.2022.101016]
  364. Brouwer CL, Wiesendanger EM, van der Hulst PC et al. Scrotal irradiation in primary testicular lymphoma: review of the literature and in silico planning comparative study. Int J Radiat Oncol Biol Phys 2013; 85: 298–308.
  365. Cheah CY, Wirth A, Seymour JF. Primary testicular lymphoma. Blood 2014; 123:486-493.
  366. Paul D Brown, Stephanie Pugh, Nadia N Laack et al. Randomized Controlled Trial Radiation Therapy Oncology Group (RTOG). Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial // Neuro Oncol. 2013 Oct;15(10):1429-37. doi: 10.1093/neuonc/not114. Epub 2013 Aug 16. ClinicalTrials.gov NCT00566852. PMID: 23956241 PMCID: PMC3779047 DOI: 10.1093/neuonc/not114
  367. Candice Jamois, David C. Turner, Leonid Gibiansky, NewTocilizumab (TCZ) Dosing Guidance for T-Cell Engaging Bispeci c Antibody-Related Cytokine Release Syndrome (CRS) in Patients (pts) with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL): Insights from Pooled Clinical Trial Safety Experience and Quantitative Clinical Pharmacology (qCP) Analyses The 65th ASH Annual Meeting . Blood 142 (2023) 1742–1744.
  368. Norbert Schmitz, Samira Zeynalova, Maike Nickelsen, CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP Journal of Clinical Oncology. Volume 34, Number 26, September 2016

Для продолжения работы требуется Registration
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Table of contents

Данный блок поддерживает скрол*